Default company panoramic image
Logo

Xeris Pharmaceuticals, Inc.

Xeris uses its novel formulation and delivery platforms to develop ready-to-use, ultra-low volume, patient-friendly injectable drugs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Austin, TX, USA
  • Currency USD
  • Founded July 2005
  • Employees 10
  • Website xerispharma.com

Company Summary

Xeris is an emerging company developing patient-friendly injectable drugs for various indications. The current paradigm for many drugs is to design formulations for delivery in water. However, the use of water creates problems often leading to a poor patient experience. By eliminating the use of water, Xeris changes the paradigm of injection and solves a number of problems adding significant value to existing and new drugs in development.

Team

  • Default avatar
    Steven Prestrelski, PhD, MBA
    CEO

    Inventor of the Xeris platform technologies, Steve is an internationally recognized expert in drug formulation & delivery with over 20 years of product development experience. He was most recently VP of Pharmaceutical R&D at Amylin where he led the Bydureon® program from Phase 2 through global regulatory filings. Prior to Amylin, Steve has worked at PowderJect, Alza and Amgen in technical and management roles.

  • Default avatar
    Douglas Baum
    President and Chief Business Officer

    Doug Baum has 20 years of business development and executive management experience within the life sciences industry. He is a co-founder of MacuCLEAR Corporation (www.macuclear.com), a clinical stage pharmaceutical company focused on developing treatments for vascular disorders of the eye. Previously, he served as VP, Global Corporate Development at Premier Research Group (PRG), Inc., a global CRO serving various life science industries.

  • Default avatar
    Yash Sabharwal, PhD
    COO/CFO

    Yash has over 15 years of experience in the operation and financing of early-stage technology companies. He was a co-founder of Optical Insights, LLC and led both the technical and business development efforts with an emphasis on financial operations as CFO from early stage inception to the sale of the company in 2005 to Roper Industries. In 2010, Yash joined Xeris as COO and CFO and has led the efforts to secure $10M in funding to date.

  • Default avatar
    John Kinzell
    EVP, Corporate Development

    John Kinzell has 25 years of operations and product development experience in the biotechnology and chemical industries. He has demonstrated skills in organizing and structuring startups for both consulting and product-based companies. Most recently, he was the Global Head of Regulatory Affairs at Arysta LifeScience, and prior to that, Head of Regulatory Affairs at Arysta where he managed all pre-registration testing and regulatory programs.

Advisors

  • Default avatar
    Andrews Kurth LLP
    Lawyer
    Unconfirmed
    Default avatar
    Padgett Stratemann
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Co-Founders and Management Team
    Unconfirmed
    Default avatar
    Central Texas Angel Network and various Family Offices
    Unconfirmed
    Default avatar
    Texas Emerging Technologies Fund
    Unconfirmed